Clinical trial Recruiting at 1 site Interventional Ages 65 to 110

Preventing medication-related side effects and falls in older adults after an ER visit

Official title: The Geriatric Emergency Department Pharmacologic Harm Prevention Project

Run by Florida Atlantic University · NCT07216846 · Data updated 2026-11-12

This project will test whether giving doctors patients' DNA results to guide prescribing can reduce medication side effects and falls in adults 65 and older who come to the emergency department after a ground-level fall.

More Fall trials

Quick facts

Study typeInterventional
Ages65 Years to 110 Years
SexAll
Enrollment1000 (estimated)
SponsorFlorida Atlantic University
Academic / other
Locations1 site (Delray Beach, Florida)
StatusRecruiting
StartedJanuary 1, 2026
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedJanuary 8, 2026
Trial IDNCT07216846 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 65 or older who come to the emergency department after a ground-level fall, particularly those taking multiple prescription medications.

Probably not a fit

Patients in hospice care or with a do-not-resuscitate order are excluded and those not taking medications that interact with common pharmacogenes or whose falls are due to acute non-medication causes may be less likely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will enroll adults aged 65 and older who present to the Delray Medical Center emergency department after a ground-level fall and randomize them to one of two pathways. The DNA Care Pathway provides treating physicians and primary care providers with patients' pharmacogenomic results to guide medication choices, while the Emergency Department Care Pathway follows usual care and shares DNA results only after study completion. Participants give a cheek swab for DNA testing, complete a fall and medication calendar, and receive monthly follow-up phone calls for six months to record falls, injuries, medication changes, and side effects. Investigators will compare rates of medication-related adverse events, especially falls and fall-related injuries, between the two groups.

Why it matters

Potential benefit: If successful, this approach could help clinicians choose safer medications and lower the risk of falls and other medication-related side effects in older adults.

How similar studies have gone: Previous pharmacogenomic programs have reduced some adverse drug reactions and informed safer prescribing, but using DNA-guided prescribing specifically to prevent falls remains relatively novel with limited direct evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients over the age of 65 with a ground level fall

Exclusion Criteria:

* hospice and/or DNR status.

Where it's running

  • Delray Medical Center
    Delray Beach, Florida, United States
    Recruiting

Study contacts

  • Principal investigator: Richard Shih, MD — Florida Atlantic University
  • Study coordinator: Richard Shih, Professor, MD
  • Email: rshih@health.fau.edu
  • Phone: 561-737-7733

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.